These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9135874)

  • 1. Clonal selection of HIV type 1 variants associated with resistance to foscarnet in vitro: confirmation by molecular evolutionary analysis.
    Nakano T; Morozumi H; Inuzuka S; Nagata M; Taguchi Y; Mizokami M; Okamoto T
    AIDS Res Hum Retroviruses; 1997 May; 13(7):563-73. PubMed ID: 9135874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1.
    Quiñones-Mateu ME; Albright JL; Mas A; Soriano V; Arts EJ
    J Virol; 1998 Nov; 72(11):9002-15. PubMed ID: 9765445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1.
    Tachedjian G; Mellors JW; Bazmi H; Mills J
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1059-64. PubMed ID: 9718121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.
    Hammond JL; Koontz DL; Bazmi HZ; Beadle JR; Hostetler SE; Kini GD; Aldern KA; Richman DD; Hostetler KY; Mellors JW
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1621-8. PubMed ID: 11353603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
    Rosowsky A; Fu H; Pai N; Mellors J; Richman DD; Hostetler KY
    J Med Chem; 1997 Aug; 40(16):2482-90. PubMed ID: 9258355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.
    Tachedjian G; Hooker DJ; Gurusinghe AD; Bazmi H; Deacon NJ; Mellors J; Birch C; Mills J
    Virology; 1995 Sep; 212(1):58-68. PubMed ID: 7545854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
    Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
    J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
    Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.
    Peters S; Muñoz M; Yerly S; Sanchez-Merino V; Lopez-Galindez C; Perrin L; Larder B; Cmarko D; Fakan S; Meylan P; Telenti A
    J Virol; 2001 Oct; 75(20):9644-53. PubMed ID: 11559796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.
    Mellors JW; Bazmi HZ; Schinazi RF; Roy BM; Hsiou Y; Arnold E; Weir J; Mayers DL
    Antimicrob Agents Chemother; 1995 May; 39(5):1087-92. PubMed ID: 7542860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point mutations in the varicella-zoster virus DNA polymerase gene confers resistance to foscarnet and slow growth phenotype.
    Visse B; Huraux JM; Fillet AM
    J Med Virol; 1999 Sep; 59(1):84-90. PubMed ID: 10440813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.
    Tachedjian G; French M; Mills J
    Antimicrob Agents Chemother; 1998 Nov; 42(11):3038-43. PubMed ID: 9797252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.
    Villena C; Prado JG; Puertas MC; Martínez MA; Clotet B; Ruiz L; Parkin NT; Menéndez-Arias L; Martinez-Picado J
    J Virol; 2007 May; 81(9):4713-21. PubMed ID: 17314158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovir-resistant (ACV(r)) herpes simplex virus type 1: emergence of foscarnet-resistant virus originating from the ACV(r) virus.
    Saijo M; Yasuda Y; Yabe H; Kato S; Suzutani T; De Clercq E; Niikura M; Maeda A; Kurane I; Morikawa S
    J Med Virol; 2002 Sep; 68(1):99-104. PubMed ID: 12210436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
    Tachedjian G; Mellors J; Bazmi H; Birch C; Mills J
    J Virol; 1996 Oct; 70(10):7171-81. PubMed ID: 8794364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV; Huismans R; Jebbink MF; Danner SA; de Boer RJ; Goudsmit J
    AIDS Res Hum Retroviruses; 2001 Jun; 17(9):807-18. PubMed ID: 11429122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.
    Bleiber G; Munoz M; Ciuffi A; Meylan P; Telenti A
    J Virol; 2001 Apr; 75(7):3291-300. PubMed ID: 11238855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil.
    de Sa-Filho DJ; Soares Mda S; Candido V; Gagliani LH; Cavaliere E; Diaz RS; Caseiro MM
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):347-53. PubMed ID: 18327988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.